Last €0.64 EUR
Change Today +0.03 / 4.92%
Volume 1.5M
As of 11:35 AM 03/5/15 All times are local (Market data is delayed by at least 15 minutes).

diaxonhit (ALEHT) Snapshot

Open
€0.62
Previous Close
€0.61
Day High
€0.66
Day Low
€0.61
52 Week High
03/5/14 - €1.02
52 Week Low
10/15/14 - €0.47
Market Cap
44.3M
Average Volume 10 Days
215.2K
EPS TTM
€-0.09
Shares Outstanding
69.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DIAXONHIT (ALEHT)

Related News

No related news articles were found.

diaxonhit (ALEHT) Related Businessweek News

No Related Businessweek News Found

diaxonhit (ALEHT) Details

Diaxonhit discovers and commercializes specialty diagnostic products in the transplantation, infectious diseases, and cancer diagnosis specialty areas. Its commercialized product includes Tétanos Quick Stick, a proprietary test, which is used in emergency clinics for the evaluation of the protective status of a patient against tetanus. The company's in-house development products comprise the BJI InoPlex kit, a test that allows the detection of infections linked to articular prosthesis; and EHT Dx15, a test for the diagnosis of thyroid cancer, as well as licensed product includes AlloMap, a gene-expression profiling based blood test for regular and non-invasive surveillance of heart transplant recipients for acute cellular rejection. It is also involved in the development of companion diagnostics for resistant and breast cancers; and tests to monitor the direct effect of drug activity. Diaxonhit was founded in 1997 and is headquartered in Paris, France.

89 Employees
Last Reported Date: 09/24/14
Founded in 1997

diaxonhit (ALEHT) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

diaxonhit (ALEHT) Key Developments

DIAXONHIT Announces Consolidated Earnings Results for the Year Ended December 31, 2014

DIAXONHIT announced consolidated earnings results for the year ended December 31, 2014. For the year, the company’s income was EUR 30.6 million compared to EUR 30.5 million as of December 31, 2013. Total annual sales reached EUR 27.9 million, an increase of 6% compared to sales of EUR 26.3 million recorded for the year 2013. This growth offset the decrease in revenues from R&D activities undertaken within the Allergan partnership.

Diaxonhit Enters into Service Sub-Licensing Agreement with the Strasbourg University Hospitals

DIAXONHIT announced that it entered into a service sub-licensing agreement with the Strasbourg University Hospitals for the performance of the CareDx Inc. AlloMap® test in a dedicated facility as its Central European Laboratory. Under this agreement, all testing activities will be performed in HUS' Central Immunology Laboratory, under the authority and exclusive responsibility of HUS and its scientific director, Professor Seiamak Bahram. The AlloMap molecular blood test is a novel method for regular and non-invasive surveillance of heart transplant recipients for acute cellular rejection. All patients' blood samples collected in heart transplant centers around Europe will be shipped to the Strasbourg facility where the AlloMap testing procedure will be performed. Test results will be sent back directly from the Central Laboratory to the clinicians, consisting primarily of cardiologists and heart surgeons. DIAXONHIT is the exclusive European distributor of the AlloMap test. It will supply the central laboratory with specific AlloMap plates and control reagents both manufactured by CareDx, the developer and licensor of AlloMap. DIAXONHIT will also supply heart transplant centers with a kit to facilitate blood samples handling and shipment. HUS' Central Immunology Laboratory was selected by DIAXONHIT for its ability to conduct the testing procedure with all necessary quality requirements to ensure the accuracy and reproducibility of AlloMap results delivered to prescribing clinicians. The HUS location in Strasbourg is also a key advantage. Centrally positioned between southern and northern Europe on the French-German border, this location will facilitate rapid handling of blood samples from any European country and ensure more efficient delivery from heart transplant centers.

Diaxonhit Announces Good Performance of BJI InoPlex(R) Test for the Diagnosis of Prosthetic Infections

DIAXONHIT announced the good performance of BJI InoPlex(R), the first blood test for the diagnosis of prosthetic joint infections at a symposium held during the 34(th) RICAI meeting in Paris, France. This performance was derived from BJI InoPlex(R) clinical validation study conducted in two French reference centers for prosthetic joint infections. A large cohort of 455 patients was recruited for this study. Prosthetic joint infections, a major public health issue Each year, nearly 3 million implants are placed in Europe and the United States, including more than 220,000 hip and knee replacements in France. About 10 to 20% of all patients undergoing replacements may experience pain or functional impairment, even long after implant surgery. Identifying whether the cause of such dysfunction is infectious or mechanical becomes necessary. If the diagnosis of prosthetic infections in the weeks or first few months following surgery is usually not a problem because clinical signs are visible, it becomes more difficult with time, thus delaying relevant care of the patient. Infections may indeed become serious complications depending on the pathogenicity of the identified bacterium and the duration of the infection. A new test that, together with the standard assessments, allows practitioners to provide earlier and more tailored patient care. Currently, diagnostic tools available to diagnose prosthetic infections have limited performances, resulting sometimes in unsuitable patient care and late diagnosis. BJI InoPlex(R) is the first test able to detect, directly in the patient's blood, antibodies against bacteria types frequently responsible for prostetic infections, including staphylococci that are the most often encountered bacteria in such infections. With this test, the result of which is made available in a few hours, whereas conventional bacteriological culture requires from several days to over a week, the practitioner receives quick qualitative information by targeted types of bacteria, which enables him, in association with conventional assessments, to accelerate initiation of relevant patient care, particularly in terms of antibiotic therapy. BJI InoPlex(R) only requires a single patient blood sample. After proper preparation, the test is carried out directly in the biology laboratory of the hospital with a standard Luminex instrument. It provides a quick result to the prescriber who is then able to offer a more personalized support to the patient.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALEHT:FP €0.64 EUR +0.03

ALEHT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
NEL ASA 1.25 NOK 0.00
View Industry Companies
 

Industry Analysis

ALEHT

Industry Average

Valuation ALEHT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.0x
Price/Book 1.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DIAXONHIT, please visit www.exonhit.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.